Status: Not yet recruiting
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity
This study is a single-center, randomized, double-blind, dose-escalation, placebo-parallel-controlled Phase I clinical trial. The primary objective is to evaluate the safety and tolerability of a single subcutaneous injection of SHR-1179 in obese participants. For the single-ascending-dose (SAD) part in obese participants, a total of 5 dose cohorts are planned for the single-dose escalation.
Participants needed: 50
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Guangdong Hengrui Pharmaceutical Co., LtdUpdated: Sep 17, 2026Locations: 1
Eligibility criteria
Healthy male or female participants aged ≥ 18 and ≤ 60 years at the time of info... [+4]
Have a documented history of diseases involving the immune system, central nervo... [+19]